Early cancer detection, some new technologies on the horizon

Urine-based biomarkers for early cancer screening test

A new study has introduced a new technique that validates urine-based biomarkers for early detection of cancer. The research team expects that this may be potentially useful in clinical settings to test urinary EV-based biomarkers for cancer diagnostics.

read more

Dr. Stegall’s comments: As I always say, the more tools we have in our tool chest, the better. One of the challenges in oncology has been detecting and monitoring cancer. I am excited to learn more about urine testing for cancer, and how it can aid us in the future.


A new method for early cancer detection

It may soon be possible to test a person for cancer with just a drop of their blood and a small machine. As part of a European research project, scientists have developed a device for detecting the HSP70 protein, which is over-expressed in patients with many types of cancer. The objective: to make it possible to diagnose cancer extremely early in the disease process, thereby improving outcomes for patients.

read more

Dr. Stegall’s comments: Heat shock proteins are important to identify. They are included on the extensive baseline testing I do in my office, and I use them to inform me of each patient’s cancer cells’ potential susceptibility to heat-based treatments such as local hyperthermia and radiation.


Ultrafast detection of a cancer biomarker enabled by innovative nanobiodevice

Researchers have developed a nanobiodevice that can quickly and effectively separate microRNA, short lengths of ribonucleic acid present in bodily fluids, from mixtures of nucleic acids. The nanobiodevice contains a unique array of nanopillars that form a strong electric force under an applied electric field, allowing high-resolution separation of microRNA in less than 100 ms. Because microRNA is a biomarker for cancer, this technology may provide a simple, noninvasive approach for detecting cancer.

read more

Dr. Stegall’s comments: As research continues to emerge on innovative lab testing for cancer, two challenges remain: are these lab tests valid on a large scale, and can they be cost effective for routine use? Hopefully the answer to both questions will be yes.

Breast Cancer Study Update

The study questions whether reliance on insufficiently-validated antibodies has led science down a dead-end path since the discovery of estrogen receptor beta (ESR2) in the

Read More »